Game-changing cancer therapy: Imugene’s VAXINIA receives FDA orphan drug status for bile tract cancer
Imugene Limited has received a significant boost with the United States Food and Drug Administration (FDA) granting Orphan Drug Designation (ODD) to its experimental therapy, ... Read More
TCR2 Therapeutics reports positive interim results for gavo-cel in early-stage solid tumors trial
TCR2 Therapeutics has reported positive interim results from its phase 1 part of the phase 1/2 clinical trial of its T-cell therapy candidate gavo-cel in ... Read More
Incyte bags Pemazyre FDA approval for cholangiocarcinoma treatment
Pemazyre FDA approval : US biopharma company Incyte has bagged accelerated approval from the US Food and Drug Administration (FDA) for Pemazyre (pemigatinib) for the ... Read More
Incyte secures FDA priority review for pemigatinib in cholangiocarcinoma
Delaware-based pharma company Incyte has secured priority review for pemigatinib from the US Food and Drug Administration (FDA) for the treatment of locally advanced or ... Read More